Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus...
29 KB (2,325 words) - 02:02, 16 July 2024
COVID-19 drug development (section Sotrovimab)
was approved for medical use in the European Union in November 2021. Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal...
90 KB (13,103 words) - 04:28, 26 July 2024
neutralization tests indicate monoclonal antibody therapies (with the exception of sotrovimab and tixagevimab/cilgavimab) were not likely to be active against the Omicron...
49 KB (4,964 words) - 04:02, 9 August 2024
severe or critical patients. It also recommended the monoclonal antibody Sotrovimab in patients with non-severe disease, but only those who are at highest...
368 KB (32,620 words) - 20:42, 22 August 2024
of antigenic sites outside the RBM, including sotrovimab (VIR-7831), S2X259 and S2H97. However, sotrovimab was not fully active against the BA.2 Omicron...
218 KB (24,589 words) - 22:10, 21 August 2024
Bamlanivimab Etesevimab Bebtelovimab Casirivimab/imdevimab Regdanvimab Sarilumab Sotrovimab Tixagevimab/cilgavimab Tocilizumab Small molecule antivirals Broad-spectrum...
180 KB (23,898 words) - 14:59, 19 August 2024
192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584. "AusPAR: Sotrovimab". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from...
136 KB (4,020 words) - 07:14, 15 August 2024
Motavizumab J06BD03 Tixagevimab and cilgavimab J06BD04 Ansuvimab J06BD05 Sotrovimab J06BD06 Regdanvimab J06BD07 Casirivimab and imdevimab J06BD08 Nirsevimab...
2 KB (264 words) - 07:33, 31 December 2022
the United States: bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab. Bamlanivimab/etesevimab was not recommended in the United States due...
76 KB (7,457 words) - 03:44, 17 June 2024
nirmatrelvir and ritonavir, and recommended conditionally Molnupiravir, Sotrovimab and Remdesivir. For severe cases WHO strongly recommended corticosteroids...
68 KB (6,414 words) - 20:36, 11 June 2024
imdevimab appear to still be effective. A preprint study suggests that sotrovimab may also be effective against Delta. Doctors in Singapore have been using...
130 KB (12,297 words) - 14:53, 16 August 2024
Odesivimab Pemivibart Rafivirumab§ Regavirumab§ Regdanvimab Sevirumab† Sotrovimab Suptavumab Tixagevimab† (+cilgavimab)† Tuvirumab§ Chimeric Cosfroviximab...
24 KB (2,654 words) - 05:16, 24 November 2023
June 2021, the country's National Health Regulatory Authority approved Sotrovimab, a monoclonal antibody, for emergency use in mild to moderate COVID-19...
78 KB (5,512 words) - 18:04, 17 June 2024
Scotland have been resolved, First Minister Nicola Sturgeon confirms. Sotrovimab is approved in the UK as a COVID antibody treatment; tests have found...
321 KB (39,650 words) - 22:16, 21 August 2024
Administration. U.S. Food and Drug Administration (March 30, 2022). "FDA updates Sotrovimab emergency use authorization". FDA. U.S. Food & Drug Administration (January...
45 KB (4,452 words) - 22:48, 9 March 2024